Orexigen Therapeutics (OREXQ) Stock Price, News & Analysis

Company Overview

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Key Stats

• Today's Range: $0.0027 to $0.0053
• 50-Day Range: $0.0053 to $0.0053
• 52-Week Range: $0.00 to $0.16
• Volume: 60,300 shs
• Average Volume: 80,439 shs
• Market Capitalization: $100.10 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OREXQ Stock Analysis - Frequently Asked Questions

How have OREXQ shares performed this year?

Orexigen Therapeutics' stock was trading at $0.0053 at the beginning of 2025. Since then, OREXQ stock has increased by 0.0% and is now trading at $0.0053.
View the best growth stocks for 2025 here.

How do I buy shares of Orexigen Therapeutics?

Shares of OREXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OREXQ
• CIK: 1382911
• Web: www.orexigen.com
• Phone: 858-875-8600
• Fax: N/A
• Employees: 132
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $33.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,887,000
• Free Float: N/A
• Market Cap: $100.10 thousand
• Optionable: Not Optionable
• Beta: 4.98